Content related to Backstory: An 18-Year Journey From Idea to FDA-Approved Therapy

A CHLA clinical trial finds that N-acetylcysteine may be a promising next-generation therapy to reduce the risk of cisplatin-induced hearing loss.

Study results are promising for an investigational drug to prevent bleeding in patients with a severe clotting disorder.

A CHLA-USC neurovascular team is bringing advanced care and innovative surgical techniques to children with cerebrovascular disorders.

Three-year-old Javier is happy and healthy and back home in Mexico after successful treatment for neuroblastoma at Children’s Hospital Los Angeles. “We are back to the life we used to have, but we see

Four investigators share their research—and how the USC/CHLA facility will help bring novel cell therapies to clinical trials faster.

A neuroimmunologist at Children’s Hospital Los Angeles led an effort to create an ICD-10 code for MOGAD—helping to speed access to critical medications.

Children’s Hospital Los Angeles dedicates annual research symposium events to childhood obesity as a driver of chronic lifetime health issues including diabetes, heart disease and liver disease.

After her son was diagnosed with a rare tumor, Melissa searched for help. She found it at CHLA in the office of Dr. Ashley Margol, one of the few experts in an innovative therapy called MEMMAT.